title: Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis.
abstract: OBJECTIVE
  To determine the clinical features of methotrexate (MTX) pneumonitis in patients treated for rheumatoid arthritis (RA).
  
  
  METHODS
  The medical records of 284 patients with RA who had been treated with oral MTX (mean followup 33.2 mo) were reviewed retrospectively.
  
  
  RESULTS
  MTX induced interstitial pneumonitis developed in 6 patients (2.1%). The affected patients were significantly older than those without MTX pneumonitis (67.3 +/- 9.8 vs 52.4 +/- 12.6 yrs, respectively; p < 0.005). The cumulative MTX dose ranged from 65 to 580 mg at the time pneumonitis developed. Five of the patients (83%) had preexisting interstitial abnormalities, while only 29 of the 278 patients without MTX pneumonitis (10%) had such abnormalities (p < 0.001). The frequency of adverse effects due to previous treatment with disease modifying antirheumatic drugs (DMARD) was 66.7% in MTX pneumonitis patients and 14.3% in the other 278 patients (p < 0.01).
  
  
  CONCLUSIONS
  Advanced age, preexisting interstitial abnormalities, and previous adverse reactions to DMARD may be associated with MTX pneumonitis. Patients with these characteristics require careful monitoring during MTX therapy.
authors.affiliation: Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohosone
authors.forename: Y
authors.initials: Y
authors.lastname: Okano
authors.forename: H
authors.initials: H
authors.lastname: Kameda
authors.forename: T
authors.initials: T
authors.lastname: Fujii
authors.forename: N
authors.initials: N
authors.lastname: Hama
authors.forename: M
authors.initials: M
authors.lastname: Hirakata
authors.forename: T
authors.initials: T
authors.lastname: Mimori
authors.forename: M
authors.initials: M
authors.lastname: Akizuki
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003404:Creatinine / Q000097:blood; D003586:Cytomegalovirus Infections / Q000175:diagnosis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D018501:Antirheumatic Agents; D003404:Creatinine; D008727:Methotrexate